Ivonescimab Wins China NMPA Approval for First-Line Squamous NSCLC, Third Indication
SMMT sits 25% above its 52-week low of $12.25.
Summary
China's NMPA approved ivonescimab plus chemotherapy for first-line squamous NSCLC, marking the drug's third approved indication in China. The approval is based on the HARMONi-6 trial, which showed statistically significant and clinically meaningful superiority in both progression-free and overall survival versus a PD-1 inhibitor plus chemotherapy — a first in any tumor type. This validates ivonescimab's potential to become a new standard of care and strengthens Summit's global development plans. The approval comes as Summit faces a going-concern warning and an FDA decision in November, making this positive regulatory milestone critical for partner Akeso and Summit's licensed territories. Co-CEOs Duggan and Zanganeh emphasized the data's strength and their commitment to accelerating global development.
At the time of this announcement, SMMT was trading at $15.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1B. The 52-week trading range was $12.25 to $30.05. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.